JP Morgan Chase’s Corbus Pharmaceuticals CRBP Stock Holding History

JP Morgan Chase’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,920	Closed	-$173K	–	6378
2021 Q1	$173K	Buy	+2,920	New	+$192K	﹤0.01%	5204

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's CRBP Position: Q3 2025 in Review

JP Morgan Chase sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 983 shares — an estimated $6.78K sold.

JP Morgan Chase first reported a position in CRBP in Q2 2016 and held it in 32 quarters. The position peaked at $2.42M in Q1 2024. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

JP Morgan Chase reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
JP Morgan Chase sold 983 Corbus Pharmaceuticals shares in Q3 2025, an estimated $6.78K.
JP Morgan Chase first reported a position in Corbus Pharmaceuticals in Q2 2016 and held it in 32 quarters.
JP Morgan Chase's Corbus Pharmaceuticals position peaked at $2.42M in Q1 2024.
81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.